Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $22.0000 (-12.04%) ($21.1500 - $25.8900) on Tue. Jan. 19, 2016. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 11.18% (three month average) | RSI | 23 | Latest Price | $22.0000(-12.04%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.2% a day on average for past five trading days. | Weekly Trend | ADMS declines -8.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(36%) IBB(34%) ARKG(25%) IWO(23%) IWM(22%) | Factors Impacting ADMS price | ADMS will decline at least -5.59% in a week (0% probabilities). VIXM(-15%) UUP(-8%) BNDX(-8%) TLT(-7%) SHY(-7%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -5.59% (StdDev 11.18%) | Hourly BBV | 0 () | Intraday Trend | -14.6% | | | |
|
Resistance Level | $24.78 | 5 Day Moving Average | $24.08(-8.64%) | 10 Day Moving Average | $24.21(-9.13%) | 20 Day Moving Average | $24.78(-11.22%) | To recent high | -28.7% | To recent low | 65% | Market Cap | $622m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |